名称 | SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study |
作者 | Shuqui Qin1; Jin Li2; Aiping Zhou3; Yanqiao Zhang4; Xianglin Yuan5; Liangjun Zhu6; Baoli Qin7; Shan Zeng8; Lin Shen9; Ying Yuan10; Weibo Wang11; Jun Liang12; Xianwen Zhang13; Feng Ye14; Ping Chen15; Huaizhang Wang16; Zhenyan Yu17; Lu Yue18; Yong Fang19; Jianping Xiong20; Jianwei Yang21; Yiye Wan22; Xianli Yin23; Wenling Wang24; Nong Xu25; Xiaohong Wang26; Zemin Xiao27; Huafang Su28; Ying Wang29; Kangsheng Gu30; Shuiping Tu31; Zishu Wang32; Bo Liu33; Xiaohua Hu34; Weixian Liu35; Xiaofeng Li36
|
发表期刊 | Cancer communications (London, England) |
语种 | 英语 |
原始文献类型 | Letter |
出版者 | WILEY |
ISSN | 2523-3548 |
EISSN | 2523-3548 |
卷号 | 44 |
期号 | 8 |
页码 | 910-914 |
DOI | 10.1002/cac2.12586 |
页数 | 5 |
WOS类目 | Oncology |
WOS研究方向 | Oncology |
WOS记录号 | WOS:001264100600001 |
收录类别 | PUBMED ; SCIE ; SCOPUS |
发布日期 | 2024-07-08 |
URL | 查看原文 |
PubMed ID | 38976318 |
通讯作者地址 | [Li, Jin]Shanghai East Hosp, Dept Med Oncol, 1,800 Yuntai Rd, Shanghai 200123, Peoples R China. |
Scopus学科分类 | Oncology;Cancer Research |
SCOPUSEID | 2-s2.0-85197681328 |
引用统计 | |
文献类型 | 其他 |
条目标识符 | https://kms.wmu.edu.cn/handle/3ETUA0LF/215748 |
专题 | 附属第一医院 第一临床医学院(信息与工程学院)、附属第一医院 附属第一医院_放化疗科 |
作者单位 | 1.Department of Oncology, Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, P. R. China.; 2.Department of Medical Oncology, Shanghai East Hospital, Shanghai, P. R. China.; 3.Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, P. R. China.; 4.Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.; 5.Department of Medical Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.; 6.Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, P. R. China.; 7.Department of Gastroenterology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China.; 8.Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.; 9.Department of Medical Oncology, Beijing Cancer Hospital, Beijing, P. R. China.; 10.Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.; 11.Department of Chemotherapy, Shandong Provincial Hospital, Jinan, Shandong, P. R. China.; 12.Department of Medical Oncology, Peking University International Hospital, Beijing, P. R. China.; 13.Department of Medical Oncology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, P. R. China.; 14.Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, P. R. China.; 15.Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, P. R. China.; 16.Department of Integrated Chinese and Western Medicine, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China.; 17.Department of Medical Oncology, Mudanjiang Tumor Hospital, Mudanjiang, Heilongjiang, P. R. China.; 18.Department of Oncology, Qingdao Municipal Hospital (Group), Qingdao, Shandong, P. R. China.; 19.Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.; 20.Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P. R. China.; 21.Department of Abdominal Oncology, Fujian Cancer Hospital, Fuzhou, Fujian, P. R. China.; 22.Department of Gastroenterology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, P. R. China.; 23.Department of Gastroenterology and Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, P. R. China.; 24.Department of Abdominal Oncology, The Affiliated Hospital of Guizhou Medical University, Guizhou, Guizhou, P. R. China.; 25.Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.; 26.Department of Abdominal Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China.; 27.Department of Oncology, The First People's Hospital of Changde City, Changde, Hunan, P. R. China.; 28.Department of Radiotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, P. R. China.; 29.Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, P. R. China.; 30.Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P. R. China.; 31.Department of Medical Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.; 32.Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, P. R. China.; 33.Department of Gastroenterology, Shandong Cancer Hospital & Institute, Jinan, Shandong, P. R. China.; 34.Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P. R. China.; 35.Department of Medical Oncology, Binzhou People's Hospital, Binzhou, Shandong, P. R. China.; 36.Department of Medical Oncology, Quanzhou First Hospital, Quanzhou, Fujian, P. R. China. |
推荐引用方式 GB/T 7714 | Shuqui Qin,Jin Li,Aiping Zhou,et al. SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. 2024. |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
查看访问统计 |
谷歌学术 |
谷歌学术中相似的文章 |
[Shuqui Qin]的文章 |
[Jin Li]的文章 |
[Aiping Zhou]的文章 |
百度学术 |
百度学术中相似的文章 |
[Shuqui Qin]的文章 |
[Jin Li]的文章 |
[Aiping Zhou]的文章 |
必应学术 |
必应学术中相似的文章 |
[Shuqui Qin]的文章 |
[Jin Li]的文章 |
[Aiping Zhou]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论